Please login to the form below

Not currently logged in
Email:
Password:

Natco Pharma

This page shows the latest Natco Pharma news and features for those working in and with pharma, biotech and healthcare.

Teva faces early rival to longer-acting Copaxone in US

Teva faces early rival to longer-acting Copaxone in US

the importance Copaxone (glatiramer acetate) has to the Israeli pharma group’s finances. ... The approval and launch is also big news for Indian company Natco Pharma, which partnered with Mylan on developing the generic and will share profits on sales.

Latest news

  • India turns down patent on Gilead's Sovaldi India turns down patent on Gilead's Sovaldi

    Last year, Sovaldi's Indian intellectual property (IP) also faced a "pre-grant" objection from domestic pharma company Natco as well as the New York-based Initiative for Medicines, Access &Knowledge ... The Indian ruling suggests other drugmakers like

  • BMS says it defends Sprycel patent in India BMS says it defends Sprycel patent in India

    BDR had been trying to secure a compulsory license to overturn BMS' 2010 Indian patent on Sprycel on the grounds of public need, a strategy which allowed Natco Pharma to start ... Towards the end of last year court documents suggested Natco was no longer

  • Bayer fails to overturn Nexavar compulsory licence in India Bayer fails to overturn Nexavar compulsory licence in India

    Bayer fails to overturn Nexavar compulsory licence in India. Natco Pharma allowed to sell cut-price version of cancer drug. ... The Intellectual Property Appellate Board (IPAB) upheld the licence awarded to Natco Pharma - which sells a cut-price version

  • India could hit Roche and BMS with compulsory licences India could hit Roche and BMS with compulsory licences

    The first compulsory licence in India was introduced last year for Bayer's liver cancer drug Nexevar (sorefinib), allowing Natco Pharma to sell a copy of the treatment that was 95 ... It is a very good move and will not just benefit Indians but possibly

  • India revokes Pfizer's patent on Sutent India revokes Pfizer's patent on Sutent

    India revokes Pfizer's patent on Sutent. Loses patent protection for kidney cancer drug after Cipla and Natco challenge. ... drugmakers Cipla and Natco Pharma in a legal challenge to Pfizer's IP.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics